Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
Holding MCRB?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.2Last Year’s EPS
-$0.31Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 38.76%
|Next Earnings Date:Mar 11, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress with SER-155 and financial restructuring through the sale of VOWST, positioning the company for future growth. However, the increased net loss and reduction in workforce present notable challenges.Company Guidance
During the Q3 2024 earnings call for Seres Therapeutics, the company provided significant guidance on its strategic focus and financial outlook. Key metrics included the completion of the VOWST sale to Nestlé Health Science, which provided an immediate capital infusion of $155 million, with future payments of approximately $73.5 million expected in 2025. The sale has enabled Seres to retire its debt, reducing operational costs and headcount by about 100 team members. Seres reported a net loss from continuing operations of $51 million for the quarter, a slight increase from $41 million the previous year, primarily due to a $23.4 million debt extinguishment loss. However, they saw a net income from discontinued operations of $139.8 million, largely due to the gain from the VOWST sale. The company anticipates funding operations into Q4 2025 and is actively seeking a partner to support the development of SER-155, a promising candidate for reducing bacterial bloodstream infections. SER-155 showed a 77% reduction in infection rates in its Phase Ib cohort 2 study, with plans to seek breakthrough therapy and QIDP designations from the FDA.Positive SER-155 Phase Ib Clinical Results
SER-155 showed a significant reduction in bacterial bloodstream infections in allo-HSCT patients, with a relative risk reduction of approximately 77% compared to placebo.
Sale of VOWST to Nestle Health Science
The sale of VOWST brought in significant immediate capital and future financial consideration, allowing the company to retire debt and streamline operations.
SER-155 Advances with FDA Designation Requests
The company has applied for breakthrough therapy designation and qualified infectious disease product designation for SER-155, with FDA feedback expected by the end of the year.
Substantial Financial Improvements
Net income from discontinued operations was $139.8 million in Q3 2024, with a gain from the sale of the VOWST business.
---
MCRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MCRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.66 | $0.59 | -10.61% |
| Aug 13, 2024 | $0.89 | $0.83 | -6.74% |
| May 08, 2024 | $1.11 | $0.75 | -32.43% |
| Mar 05, 2024 | $1.14 | $1.06 | -7.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Seres Therapeutics (MCRB) report earnings?
Seres Therapeutics (MCRB) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Seres Therapeutics (MCRB) earnings time?
Seres Therapeutics (MCRB) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MCRB EPS forecast?
MCRB EPS forecast for the fiscal quarter 2024 (Q4) is -$0.2.
---